Biomarkers and translational research and precision medicine

33P - Germline PALB2 heterozygous mutations in breast cancers: Haploinsufficiency paradigm

Authors
  • Quchang Ouyang (Changsha, China)
  • Zhe-Yu Hu (Changsha, China)
  • Liping Liu (Changsha, China)
  • Jianxiang Gao (Changsha, China)
  • Hui Wu (Changsha, China)
  • Jun Lu (Changsha, China)
  • Ning Xie (Changsha, China)
  • Can Tian (Changsha, China)
  • Zhentian Liu (Beijing, China)
  • Yaping Xu (Beijing, China)
Speakers
  • Quchang Ouyang (Changsha, China)

Previous ePoster
30P - Update on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer

Next ePosters
34P - Comparison of HER2, estrogen and progesterone receptor expression profiles of primary tumor and synchronous axillary lymph node metastases in 159 breast cancer patients - indicating tumoral heterogeneity
35P - Downregulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in breast cancer: A new insight into the mechanism of induction of antitumor immunity
No ePoster preview available
36P - Endocrine implications in male breast cancer in Bulgaria
38P - Defining the physiological miRNA landscape in nipple aspirate fluid
40P - WNT, Hedgehog and NOTCH signaling pathways in triple negative breast cancer with high and low content of cancer stem cells
42P_PR - Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study
43P - CIP2A as a novel target to combat basal like breast cancer
46P - BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience
49P - The metastatic potential of grade I breast carcinoma of no special type: A deep insight into putative molecular mechanisms
50P - ER pathway activity score as a predictive biomarker to improve stratification for neoadjuvant endocrine therapy